Cargando…
The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
BACKGROUND: While adjuvant chemotherapy benefits patients with pancreatic ductal adenocarcinoma (PDAC), the importance of the time to initiation of adjuvant therapy remains unclear. AIM: This study seeks to better understand whether the timing of postoperative chemotherapy initiation affects long‐te...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552002/ https://www.ncbi.nlm.nih.gov/pubmed/34245139 http://dx.doi.org/10.1002/cnr2.1390 |
_version_ | 1784591289266733056 |
---|---|
author | Sugumar, Kavin Hue, Jonathan J. De La Serna, Solanus Rothermel, Luke D. Ocuin, Lee M. Hardacre, Jeffrey M. Ammori, John B. Winter, Jordan M. |
author_facet | Sugumar, Kavin Hue, Jonathan J. De La Serna, Solanus Rothermel, Luke D. Ocuin, Lee M. Hardacre, Jeffrey M. Ammori, John B. Winter, Jordan M. |
author_sort | Sugumar, Kavin |
collection | PubMed |
description | BACKGROUND: While adjuvant chemotherapy benefits patients with pancreatic ductal adenocarcinoma (PDAC), the importance of the time to initiation of adjuvant therapy remains unclear. AIM: This study seeks to better understand whether the timing of postoperative chemotherapy initiation affects long‐term outcomes in PDAC. METHODS AND RESULTS: A systematic literature search was performed in Medline, Embase, and Cochrane Library in March 2020. Studies focused on the association between the timing of adjuvant therapy on long‐term outcomes in resected PDAC patients were included. The impact of early and delayed therapy as defined by the respective studies was evaluated using forest plot analysis. Overall survival (OS) and disease‐free survival (DFS) served as primary endpoints. Out of 3099 published articles, 10 retrospective studies met inclusion criteria. Combined, these studies included clinical data of 13 344 patients. The cut off used to define “early” and “delayed” treatment groups varied in the included studies ranging from 3 to 12 weeks. Due to this heterogeneity, a sub‐group analysis of three time cut offs was performed: 3 to 5 weeks, 6 to 8 weeks, and 9 to 12 weeks. There was a significant decrease in OS and DFS when adjuvant therapy was delayed by 3 to 5 weeks after surgery (OS, pooled hazard ratio [HR] = 1.86, 95% confidence interval [CI] = 1.25‐2.78; DFS, pooled HR = 1.62, 95% CI = 1.12‐2.34). However, due to small sample size and limited studies in this subgroup analysis, the results may be indeterminate. There was no significant decrease in OS with delayed initiation of adjuvant therapy by 6 to 8 weeks and 9 to 12 weeks. Similarly, delay in adjuvant therapy beyond 3‐5 weeks. CONCLUSIONS: There was no conclusive evidence suggesting improved survival in patients starting treatment at various time cut offs. Studies investigating the extreme ends of the time‐to‐treatment spectrum may prove more informative. |
format | Online Article Text |
id | pubmed-8552002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85520022021-11-04 The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis Sugumar, Kavin Hue, Jonathan J. De La Serna, Solanus Rothermel, Luke D. Ocuin, Lee M. Hardacre, Jeffrey M. Ammori, John B. Winter, Jordan M. Cancer Rep (Hoboken) Original Articles BACKGROUND: While adjuvant chemotherapy benefits patients with pancreatic ductal adenocarcinoma (PDAC), the importance of the time to initiation of adjuvant therapy remains unclear. AIM: This study seeks to better understand whether the timing of postoperative chemotherapy initiation affects long‐term outcomes in PDAC. METHODS AND RESULTS: A systematic literature search was performed in Medline, Embase, and Cochrane Library in March 2020. Studies focused on the association between the timing of adjuvant therapy on long‐term outcomes in resected PDAC patients were included. The impact of early and delayed therapy as defined by the respective studies was evaluated using forest plot analysis. Overall survival (OS) and disease‐free survival (DFS) served as primary endpoints. Out of 3099 published articles, 10 retrospective studies met inclusion criteria. Combined, these studies included clinical data of 13 344 patients. The cut off used to define “early” and “delayed” treatment groups varied in the included studies ranging from 3 to 12 weeks. Due to this heterogeneity, a sub‐group analysis of three time cut offs was performed: 3 to 5 weeks, 6 to 8 weeks, and 9 to 12 weeks. There was a significant decrease in OS and DFS when adjuvant therapy was delayed by 3 to 5 weeks after surgery (OS, pooled hazard ratio [HR] = 1.86, 95% confidence interval [CI] = 1.25‐2.78; DFS, pooled HR = 1.62, 95% CI = 1.12‐2.34). However, due to small sample size and limited studies in this subgroup analysis, the results may be indeterminate. There was no significant decrease in OS with delayed initiation of adjuvant therapy by 6 to 8 weeks and 9 to 12 weeks. Similarly, delay in adjuvant therapy beyond 3‐5 weeks. CONCLUSIONS: There was no conclusive evidence suggesting improved survival in patients starting treatment at various time cut offs. Studies investigating the extreme ends of the time‐to‐treatment spectrum may prove more informative. John Wiley and Sons Inc. 2021-07-10 /pmc/articles/PMC8552002/ /pubmed/34245139 http://dx.doi.org/10.1002/cnr2.1390 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Sugumar, Kavin Hue, Jonathan J. De La Serna, Solanus Rothermel, Luke D. Ocuin, Lee M. Hardacre, Jeffrey M. Ammori, John B. Winter, Jordan M. The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis |
title | The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis |
title_full | The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis |
title_fullStr | The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis |
title_full_unstemmed | The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis |
title_short | The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis |
title_sort | importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: a systematic review and meta‐analysis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552002/ https://www.ncbi.nlm.nih.gov/pubmed/34245139 http://dx.doi.org/10.1002/cnr2.1390 |
work_keys_str_mv | AT sugumarkavin theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT huejonathanj theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT delasernasolanus theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT rothermelluked theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT ocuinleem theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT hardacrejeffreym theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT ammorijohnb theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT winterjordanm theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT sugumarkavin importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT huejonathanj importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT delasernasolanus importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT rothermelluked importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT ocuinleem importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT hardacrejeffreym importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT ammorijohnb importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis AT winterjordanm importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis |